Cargando…

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine

INTRODUCTION: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM) despite advances in chelation therapy. The aim of this study was to compare the effectiveness and safety of deferasirox (DFX) and deferoxamine (DFO) as iron-chelating agents in patients with transfu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan, Mohamed Abdel Malik, Tolba, Omar Atef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Electronic physician 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930264/ https://www.ncbi.nlm.nih.gov/pubmed/27382454 http://dx.doi.org/10.19082/2425

Ejemplares similares

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox
por: Ghazanfari, Azam, et al.
Publicado: (2019)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran
por: Saiyarsarai, Parisa, et al.
Publicado: (2020)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy
por: Senol, Sefika Pinar, et al.
Publicado: (2016)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

The iron chelator deferoxamine decreases myeloma cell survival
por: Yang, Feifei, et al.
Publicado: (2021)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

P1451: PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX: RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY
por: Veneziano, Mathilde, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials
por: Xia, Sujian, et al.
Publicado: (2013)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
por: Ricchi, Paolo, et al.
Publicado: (2015)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience
por: Jethani, Jitendra, et al.
Publicado: (2010)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

Effects of oral iron chelator deferasirox on human malignant lymphoma cells
por: Choi, Jong Gwon, et al.
Publicado: (2012)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016)

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
por: Vini, Dimitra, et al.
Publicado: (2011)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Successful chelation in beta-thalassemia major in the 21(st) century
por: Fragodimitri, Christina, et al.
Publicado: (2023)

Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia
por: Goulas, Vasilis, et al.
Publicado: (2012)

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
por: Di Tucci, Anna Angela, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_r3531vr5u58h24vn3pgf36vtvr